APRE News and Press, Aprea Therapeutics Inc. From 03/26/20

BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today reported financial results for the three month...

Initial public offerings offer public market investors the earliest chance to own a piece of a promising company. Capital-intensive fields like drug development have continued to witness a stream of IPOs -- some more successful than others. Besides raising cash for company operations, a public ...

BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Gregory S. We...

Aprea Therapeutics  (NASDAQ: APRE) announced today that the Food and Drug Administration has given its breakthrough therapy designation to the company's lead drug candidate, APR-246. It is being tested in a cocktail with Azacitidine (a type of chemotherapy) to treat myelodysplastic syndr...

Thinly traded Aprea Therapeutics ( APRE -0.2% ) announces  Breakthrough Therapy status in the U.S. for lead candidate APR-246, combined with chemo agent azacitidine, for the treatment of myelodysplastic syndromes (MDS) with a susceptible TP53 mutation. More news on: Aprea Therapeut...

BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that the U.S. Food and Drug Administration ...

BOSTON, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, today announced that Christian S. Schade, President & C...

Investing in IPO stocks  can be fun, but also risky. There can be a scarcity of information about a brand new equity. And sometimes the underwriters intentionally lowball the value of a company, in order to hype the stock (and reward the bank's clients who bought shares on the cheap). None...

BOSTON, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting. Both trials are evaluating the safety an...

Relatively recent IPO Aprea Therapeutics ( APRE +17.2% ) is up on average volume, a modest 127K shares, adding to its breakout after a data presentation on lead candidate APR-246 at ASH on Monday. More news on: Aprea Therapeutics, Inc., Healthcare stocks news, Stocks on the move, R...